• This restructuring will support the company’s priorities by realigning the loan with the projected development and commercialization schedules of NBTXR3.
• The final loan amendment could be finalized during the fourth quarter of 2022.
Paris, France ; Cambridge, Massachusetts (USA); September 12, 2022 – NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clinical-stage biotechnology company pioneering physics-based approaches to expand treatment options for patients with today announces that an agreement in principle has been obtained from the European Investment Bank (“EIB”) to restructure the €30.7 million loan agreement signed in 2018.